Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Diagnosis and Management of Acral Lentiginous Melanoma

(2018) Yoshiyuki Nakamura et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations

(2016) Anna Sara Navazio et al.   BREAST CANCER RESEARCH AND TREATMENT

Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry

(2016) Jinhyun Cho et al.   INVESTIGATIONAL NEW DRUGS

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis

(2014) Simon J. Furney et al.   Pigment Cell & Melanoma Research

The melanoma revolution: From UV carcinogenesis to a new era in therapeutics

(2014) J. A. Lo et al.   SCIENCE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

(2011) Zhihong Chi et al.   BMC CANCER

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD